Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03341806 · ClinicalTrials.gov registry record · Phase 1
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
A Phase 1 study of Glioblastoma and GBM, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03341806: Completed Phase 1 study of Glioblastoma and GBM, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03341806 is a Phase 1 study of Glioblastoma and GBM that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 13 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03341806, a Phase 1 study of Glioblastoma and GBM, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to characterize the safety and tolerability of avelumab in combination with Laser Interstitial Thermal Therapy (LITT) for blood barrier disruption in patients with recurrent glioblastoma.
Primary Outcome
Toxicity will be measured by severity of Adverse events with toxicity grading defined by Cancer Therapy Evaluation Program's (CTEP) v4.0 of National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) scale.
Conditions Studied
Interventions
- DRUG Avelumab
- COMBINATION_PRODUCT MRI-guided LITT therapy
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-06-13 |
| Est. Completion | 2021-10-13 |
| Phase | Phase 1 |
What the finished NCT03341806 record still lists
NCT03341806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Avelumab is the first listed.
NCT03341806 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03341806 about?
NCT03341806 is a clinical study titled "Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma". The purpose of the study is to characterize the safety and tolerability of avelumab in combination with Laser Interstitial Thermal Therapy (LITT) for blood barrier disruption in patients with recurrent glioblastoma.
What is the current status of trial NCT03341806?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2018-06-13. Estimated completion is 2021-10-13.
What conditions does trial NCT03341806 study?
This clinical trial studies the following conditions: Glioblastoma, GBM.
What interventions are being tested in trial NCT03341806?
The interventions under investigation include: Avelumab (DRUG), MRI-guided LITT therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03341806?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03341806 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03341806's enrollment target sits among peer trials
13 178th of 199 higher than 21 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI